Preventing bone loss in renal transplant recipients with vitamin D.


Very rapid bone loss, osteopenia, and osteoporosis have been documented in the first 6 to 12 mo after renal transplantation. Investigated was the effect of treatment with active vitamin D on the prevention of posttransplantation bone loss. Forty adult men who were recent renal transplant recipients were enrolled onto the study. Patients were randomized into two groups: group 1 received daily alfacalcidol 0.5 micro g by mouth, and group 2 (control) received placebo. Every patient in both groups received daily 500-mg calcium carbonate supplements. Parameters of bone metabolism and bone mineral density measured at three sites were assessed before and after the study period. Bone mineral density was increased by 2.1%, 1.8%, and 3.2% at lumbar spine, femoral neck, and forearm, respectively, in group 1, whereas it decreased by 3.2%, 3.8%, and 1.8% at the same sites in the control group (P < 0.05). Serum intact parathyroid hormone level decreased significantly in group 1 compared with the control group (P = 0.003). Early bone loss that occurs during the first 1 yr after renal transplantation could be prevented by alfacalcidol. Use of alfacalcidol early after transplantation is safe and well tolerated.

Citations per Year

4,990 Citations

Semantic Scholar estimates that this publication has 4,990 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{ElAgroudy2003PreventingBL, title={Preventing bone loss in renal transplant recipients with vitamin D.}, author={Amgad El-Baz El-Agroudy and A El-Husseini and Moharam F El-Sayed and Mohamed A. Ghoneim}, journal={Journal of the American Society of Nephrology : JASN}, year={2003}, volume={14 11}, pages={2975-9} }